N/A N=53 Internet and Telephone Support Intervention for Stroke Caregivers
Depression · Quality of Life · Recovery of Function
Primary: Change in Depressive Symptoms — -2.31; 1.00; .08; 3.9 score on a scale
Clinical Trial Search
Completed trials with posted results — search by concept, filter by the parameters that matter at the bedside.
Phase 3 N=240 The Study of Nasal Insulin in the Fight Against Forgetfulness (SNIFF)
Amnestic Mild Cognitive Impairment · Alzheimer's Disease
Primary: Change in Global Measure of Cognition as Measured by the Alzheimer's Disease Assessment Scale-Cognitive 12 (ADAS-Cog12) — 3.893; 3.867; 7.091; 6.164 Modeled change score…
Phase 2 N=30 Meloxicam vs Placebo for Mobilization
Non-Hodgkin's Lymphoma · Hodgkin's Lymphoma · Multiple Myeloma
Primary: Numbers of Circulating CD34+ Cells on the First Day of Apheresis — 26; 30.7 Cells per microliter
Phase 3 N=894 Study of Efficacy and Safety of QAW039 in Patients With Severe Asthma Inadequately Controlled With Standard of Care Asthma Treatment.
Asthma
Primary: Rate of Moderate-to-severe Asthma Exacerbations During the 52-week Treatment Period in High Eosinophils Subpopulation — 0.97; 0.77; 0.93 events/year — p=0.800
Phase 2 N=320 Safety and Immunogenicity of Norovirus GI.1/GII.4 Bivalent Virus-Like Particle Vaccine in an Elderly Population
Norovirus
Primary: Percentage of Participants With a 4-Fold Rise or Greater in Serum Anti-norovirus Antibody Titers for Both GI.1 and GII.4 Virus Like Particles (VLP) as Measured by…
Phase 2 N=9 A Study of ALN-PCSSC in Participants With Homozygous Familial Hypercholesterolemia (HoFH)
Homozygous Familial Hypercholesterolemia
Primary: Percentage Change From Day 1 to Day 90 in LDL-C — -12.26 percent change
Phase 2 N=254 Trial of Cytisine in Adult Smokers
Smoking Cessation
Primary: Primary Efficacy Analysis of Primary Outcome Measure: Percentage of Expected Cigarettes Smoked Per Participant During Study Treatment — 26.62; 25.04; 47.10; 29.40…
Phase 2 N=192 Study to Evaluate the Safety, Tolerability, and Efficacy of Vesatolimod in Combination With Tenofovir Disoproxil Fumarate (TDF) in Adults With Chronic Hepatitis B (CHB) Infection Who Are Currently Not Being Treated
Chronic Hepatitis B
Primary: Mean Change (Measured in log10 IU/mL) in Hepatitis B Surface Antigen (HBsAg) From Baseline at Week 24 — -0.163; -0.056; -0.146; -0.036 log10 IU/mL — p=0.227
Phase 1 N=24 A Hepatic Impairment Study for PF-04965842.
Hepatic Impairment
Primary: Maximum Observed Plasma Concentration (Cmax) for PF-04965842 — 1352; 1276; 1426 nanogram per milliliter (ng/mL)
Phase 2 N=48 Sulforaphane for the Treatment of Young Men With Autism Spectrum Disorder
Autism Spectrum Disorder · Autistic Disorder · Neurodevelopmental Disorder
Primary: Social Responsiveness Scale-2 (SRS-2) Total Score at Baseline — 75.6; 72.6 T-score — p=0.331
N/A N=41 Longitudinal Study of Dental Implant Therapy in HIV Positive Patients
Dental Implant
Primary: Number of Implants Functioning in HIV Positive Subjects Compared to HIV Negative Subjects — 28; 25 implants
N/A N=20 Enoxaparin Versus Aspirin in Patients With Cancer and Stroke
Cancer Patients First-ever Acute Ischemic Stroke
Primary: Safety Outcomes — 1; 0; 0; 3 Participants
N/A N=15 The Evaluation of a Nasal Pillows Mask for the Treatment of Obstructive Sleep Apnea (OSA) in NZ
Obstructive Sleep Apnea
Primary: Participants Choose the Toffee Mask Based on First Impressions Over 3 Market Leading Masks — 4 Participants
Phase 2 N=61 A Study to Evaluate the Efficacy, Immunogenicity and Safety in a Sporozoite Challenge Model of a Fractional Booster Dose of GSK Biologicals' Candidate Malaria Vaccine Administered to Previously Vaccinated Healthy Malaria-naïve Adults
Malaria
Primary: Number of Subjects Reporting Plasmodium Falciparum (P. Falciparum) Parasitemia (Defined by a Positive Blood Slide) Following Sporozoite Challenge (in All Study Groups…
N/A N=260 MICRO Study: Detecting Bacterial Infections Related to Orthopaedic Surgical Implants
Open Reduction and Internal Fixation of Extremity Fractures
Primary: Number of Blood Samples With High Levels of Absorbance Via ELISA for Patients (Greater Than 1.5 Ratio Compared to Control Human Serum) — 48; 53 blood draw samples